Inovio Pharma (INO)

Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.

Count on the Advancement of DNA Medicine with Inovio Stock

By Louis Navellier and the InvestorPlace Research Staff, Editor, Growth Investor Nov 30, 2020

If you're thinking that INO stock is just a wager on a Covid-19 vaccine candidate, think again. Inovio's pipeline is robust and diverse.

Pfizer, Moderna Lead the Vaccine Race: Here’s Where 7 Other Top Vaccine Stocks Stand

By Josh Enomoto, InvestorPlace Contributor Nov 24, 2020

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here’s how this affects other Covid-19-related biotech stocks.

Prepare for Phase 2 and a Comeback for Inovio

By David Moadel, InvestorPlace Contributor Nov 24, 2020

Is INO stock nothing more than a post-pandemic pop-and-drop story? Don't count Inovio out as a crucial funding source offers timely support.

Inovio Gets the Go-Ahead But It’s Probably Too Late

By Will Ashworth, InvestorPlace Contributor Nov 20, 2020

Inovio got the go-ahead from the FDA on Nov. 16 to resume its Phase 2 clinical trial. Is INO stock worth betting on this late in the game?

Inovio Pharmaceutical’s FDA Plight Makes It a Highly Risky Bet

By Muslim Farooque Nov 18, 2020

INO stock has tumbled in the past few months. Inovio needs the FDA to bail it out by allowing the advanced trials of its vaccine to begin.

The Clock Is Ticking for Inovio Stock

By Louis Navellier and the InvestorPlace Research Staff, Editor, Growth Investor Nov 17, 2020

The FDA recently lifted the clinical hold on Inovio's Covid-19 vaccine candidate. The result could mean huge returns for INO stock.

Inovio Has Little to Show for Its Covid-19 Efforts

By Mark R. Hake, CFA Nov 17, 2020

Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.

At This Point, Go Ahead and Count Inovio Pharmaceuticals Out of the Vaccine Race

By Faisal Humayun Nov 16, 2020

INO stock is a purely speculative bet. I don't see the company being among the few that deliver a vaccine against Covid-19.

Can Inovio Benefit From All Of Its Vaccine Delays?

By Chris Markoch Nov 11, 2020

Shares of Inovio (NASDAQ:INO) are trading near a six-month low. The company is being battered by delays in getting its Covid-19 vaccine candidate into Phase....

Avoid Taking a Bet on the Deep Correction In Inovio Stock

By Chris Tyler, InvestorPlace Contributor Nov 2, 2020

Small-cap biotechs are inherently challenging. With a failed INO-4800 timeline, INO stock increasingly finds itself back in this group.

Avoid Inovio Pharmaceuticals Stock Until the FDA Greenlights Trials

By Ian Cooper Oct 30, 2020

While I’d like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can’t. Avoid INO stock for now.

Inovio Investors Need FDA to Write Positive Prescription for Stock Gains

By Todd Shriber, InvestorPlace Contributor Oct 29, 2020

The bad news is that the FDA recently halted the Inovio trial. Think about that for a moment. The world is in dire of need of a Covid-19 vaccine and the U.S. is engaged “Operation Warp Speed” to get a vaccine to market, but here's a regulator telling Inovio to pump the brakes.